The Cost of Alzheimer Drug Treatment

AbstractThe anti-amyloid drug donanemab is approved In the United States and Europe for treatment of early symptomatic Alzheimer’s disease (mild dementia)in adults with confirmed amyloid pathology. It delays the progression of disease. Evolocumabwas also reported to lower the risks of heart attacks andAlzheimer. In view of longevity and continued early Alzheimer recognition, we planned to compare costs of donanemab and evolocumab with otherdrug classes. Methods: Drug costs were obtained from Google search and yearly cost calculated. Results: Yearly costs of evolocumab were $6,840. Donanemab was more expensive at $32,000. Pembrolizumab was $160,00, durvalumab $115,000,Osimertinib $100,000, semaglutide $12,000, proposed 9-month ivonescimab $188,000. Conclusions: Donanemab $32,000 yearly cost was higher than evolocumab at $6,840. Both drugs were reasonably priced as compared with otherclasses. Considering longevity, the overall worldwide Alzheimerfuture management would be too costly to be affordable.